Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 5Recruiting 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 33Gastrointestinal 28CNS 23Genitourinary 17Dermatologic 11Head & Neck 9Breast 6Sarcoma 4Other solid neoplasm 3Tumor-Agnostic 2Other neoplasm 1Gynecologic 1Endocrine 1

Conditions

Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Carcinoma, Hepatocellular 1Adrenal Gland Neoplasms 1

Interventions

Everolimus 10lanreotide 4Capecitabine 4pasireotide 3lutetium Lu 177 dotatate 3lenvatinib 3fosbretabulin 3Temozolomide 3Sorafenib 3Paclitaxel 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Filgrastim 3Erlotinib Hydrochloride 3Doxorubicin 3trifluridine tipiracil drug combination 2surufatinib 2pembrolizumab 2pegfilgrastim 2gallium Ga 68 dotatate 2durvalumab 2dactolisib 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Sunitinib 2Rosiglitazone 2Radiotherapy 2Panobinostat 2Mitotane 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Radiosurgery × Endocrine × Clear all
NCT04785287 2026-03-03

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

M.D. Anderson Cancer Center

Phase 1/2 Terminated
13 enrolled
EndocrineGastrointestinalThoracic

Adrenal Gland Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡